Title:Clinical Analysis of Resemblance and Dissimilarities of Glucagon-like Peptide-1 Receptor Agonists: Therapeutic Approach Towards the Management of Diabetes Mellitus
Volume: 20
Issue: 1
Author(s): Sashi, Kajal Rani, Komal Rani, Ankita, Vineet Mittal, Deepak Kaushik, Manish Dhall, Prabhjeet Kaur Bamrah, Tarun Kumar*, Manisha Pandey*, Neha Jain and Ashwani Arya*
Affiliation:
- Department of Pharmaceutical Sciences,
Central University of Haryana, Mahendergarh, 123031, Haryana, India
- Department of Pharmaceutical Sciences,
Central University of Haryana, Mahendergarh, 123031, Haryana, India
- Department of Pharmaceutical Education and Research, South Campus, Bhainswal Kalan, BPS
Women University, Khanpur Kalan, Sonepat, Haryana, India
Keywords:
GLP-1, type 2 diabetes mellitus, β-cells, insulin, exenatide, incretin mimetics.
Abstract:
One of the classes of injective antidiabetic agents includes Glucagon-like peptide-1 receptor
agonists (GLP-1RA) which ameliorate glycemia and numerous atherosclerosis-related factors in
individuals prone to Type 2 diabetes mellitus (T2-DM) disorder.
Methods: The review paper targeted the role of GLP-1RA in managing DM. The literature published
during the last decades in several data-based searches (PubMed, Scopus, ScienceDirect) was reviewed
and compiled the therapeutic uses of GLP-1 RA in the management of DM. In this review,
we have discussed GLP-1RA and its role in the management of diabetes mellitus.
Results and Discussion: Disrupted homeostasis marks insulin resistance and β-cell deterioration as
two major indications of T2-DM. β-cells failure (~80% of functioning of β-cell) and insulin resistance
in the liver and muscles are primarily susceptive to physiological defects. GLP-1RAs if administered
for a prolonged period also cause a loss in weight through the activation of receptors of GLP-1 found
in hypothalamic satiety centers which control appetite and decrease intake of calories. They not only
assist in controlling blood glucose but also improve β- cell function and post–diabetic conditions
namely hyperlipidemia, obesity, and hypertension.
Conclusion: It was concluded that GLP-1RA has a new therapeutic approach to the management of
DM. Hence, GLP-1RA provides distinctive and innovative evolution for the treatment of T2-DM.
